SCHEMBL2843486

SCHEMBL2843486

c1cc(-n2cncn2)cc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 13/20 0.42
PI4KA P42356 3/20 0.41
PIK3CG P48736 3/20 0.41
PI4KB Q9UBF8 3/20 0.41
PIK3CA P42336 2/20 0.41
PIK3CD O00329 1/20 0.40
PDGFRB P09619 4/20 0.38
KIT P10721 4/20 0.38
PDGFRA P16234 4/20 0.38
FLT3 P36888 4/20 0.38
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
QPCT Q16769 1/20 0.36
USP30 Q70CQ3 1/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845143 0.84 CSF1R (0.41) CSF1RPI4KAPIK3CGPI4KBPDGFRB
SCHEMBL2845141 0.84 CSF1R (0.41) CSF1RPI4KAPIK3CGPI4KBPDGFRB
SCHEMBL2846605 0.79 CSF1R (0.47) CSF1RPI4KAPIK3CGPI4KBPIK3CD
SCHEMBL2845197 0.78 NPC1 (0.43) CSF1RPI4KAPIK3CGPI4KBPIK3CA
SCHEMBL2844397 0.78 CSF1R (0.49) CSF1RPI4KAPIK3CGPI4KBPIK3CD
SCHEMBL2677488 0.77 CSF1R (0.55) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2843153 0.76 MAPT (0.44) CSF1RPI4KAPIK3CGPI4KBPIK3CA
SCHEMBL2676754 0.76 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2677134 0.76 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL4550946 0.76 CSF1R (0.58) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
EP-2152700-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE Novartis Ag (CH) 2010-02-17 EP disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885PI4KA 2704/4885PIK3CG 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.